Chlamydia trachomatis

Published on 22/03/2015 by admin

Filed under Pediatrics

Last modified 22/03/2015

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 1252 times

Chapter 218 Chlamydia trachomatis

Chlamydia trachomatis is subdivided into 2 biovars: lymphogranuloma venereum (LGV) and trachoma, which is the agent of human oculogenital diseases other than LGV. Although the strains of both biovars have almost complete DNA homology, they differ in growth characteristics and virulence in tissue culture and animals. In developed countries, C. trachomatis is the most prevalent sexually transmitted disease, causing urethritis in men, cervicitis and salpingitis in women, and conjunctivitis and pneumonia in infants.

218.1 Trachoma

Trachoma is the most important preventable cause of blindness in the world. It is caused primarily by the A, B, Ba, and C serotypes of C. trachomatis. It is endemic in the Middle East and Southeast Asia and among Navajo Indians in the southwestern USA. In areas that are endemic for trachoma, such as Egypt, genital chlamydial infection is caused by the serotypes responsible for oculogenital disease: D, E, F, G, H, I, J, and K. The disease is spread from eye to eye. Flies are a common vector.

Trachoma begins as a follicular conjunctivitis, usually in early childhood. The follicles heal, leading to conjunctival scarring that can result in an entropion, with the eyelid turning inward so that the lashes abrade the cornea. It is the corneal ulceration secondary to the constant trauma that leads to scarring and blindness. Bacterial superinfection can also contribute to scarring. Blindness occurs years after the active disease.

Trachoma can be diagnosed clinically. The World Health Organization (WHO) suggests that at least 2 of 4 criteria must be present for a diagnosis of trachoma: lymphoid follicles on the upper tarsal conjunctivae, typical conjunctival scarring, vascular pannus, and limbal follicles. The diagnosis is confirmed by culture or staining tests for C. trachomatis performed during the active stage of disease. Serologic tests are not helpful clinically because of the long duration of the disease and the high seroprevalence in endemic populations.

Poverty and lack of sanitation are important factors in the spread of trachoma. As socioeconomic conditions improve, the incidence of the disease decreases substantially. Endemic trachoma has been controlled in most instances by administering topical tetracyclines (or, rarely, erythromycin ointment) daily for periods of 6-10 wk or intermittently over a 6-mo period. Oral doxycycline is effective but is contraindicated in children <8 yr of age. Oral erythromycin requires frequent dosing, which is impractical in the control of endemic trachoma. Several studies have reported that 1-6 doses of oral azithromycin are equivalent to 30 days of treatment with topical oxytetracycline/polymyxin ointment. The WHO recommends single-dose azithromycin (20 mg/kg, maximum 1g) for the treatment of trachoma in children. A study from Tanzania demonstrated that mass treatment with a single dose of azithromycin to all the residents of a village dramatically reduced the prevalence and intensity of infection. This effect continued for 2 years after treatment, probably by interrupting the transmission of ocular C. trachomatis infection.

218.2 Genital Tract Infections

Diagnosis

Definitive diagnosis of genital chlamydial infection is accomplished by isolation of the organism in tissue culture and confirmed by microscopic identification of the characteristic inclusions using fluorescent antibody staining in culture specimens obtained from the urethra in men and the endocervix in women. Care should be taken to obtain epithelial cells, not only discharge. C. trachomatis can be cultured in cycloheximide-treated HeLa, McCoy, and HEp-2 cells. Chlamydia culture has been further defined by the Centers for Disease Control and Prevention (CDC) as isolation of the organism in tissue culture and as confirmation of the characteristic intracytoplasmic inclusions by fluorescent antibody staining.

Alternatively, a nonculture method, specifically a nucleic acid amplification test (NAAT) can be used. These tests have high sensitivity, perhaps even detecting 10-20% greater than culture, while retaining high specificity. Three Food and Drug Administration (FDA)-approved NAATs are comercially available for detecting C. trachomatis: polymerase chain reaction (PCR; Amplicor Chlamydia test, Roche Molecular Diagnostics, Nutley, NJ), strand displacement amplification (SDA; ProbeTec, BD Diagnostic Systems, Sparks, MD), and transcription-mediated amplification (TMA; Amp CT, Gen-Probe, San Diego, CA). PCR and SDA are DNA amplification tests that use primers that target gene sequences on the cryptogenic C. trachomatis